O-RAN ALLIANCE Announces Cooperation with ATIS, Activities at MWC Barcelona 2023, 7th Release of Open Software and New OTICs
New MoU between O-RAN ALLIANCE and ATIS opens the opportunity for ATIS adopting O-RAN specifications
O-RAN ALLIANCE and ATIS signed a Memorandum of Understanding to further both organizations’ mutual objectives to advance the industry towards more intelligent, open, virtualized and global standards-compliant Radio Access Networks (RAN).
“O-RAN is welcoming the opportunity to work with ATIS,” said Alex Jinsung Choi, Chairman of the O-RAN ALLIANCE and SVP Group Technology at Deutsche Telekom. “We look forward to the opportunity to consider ATIS adopting O-RAN specifications for ATIS Open RAN standards and working together to define the next generation of open and intelligent RAN technology.”
O-RAN ALLIANCE event and demos at MWC Barcelona to bring latest updates from the open RAN ecosystem
O-RAN ALLIANCE plans to hold its next industry event on February 28, 2023 from 15:30-16:30 CET at MWC Barcelona 2023, hosted by Deutsche Telekom at Hall 3 Stand 3M31. The event will include:
- Keynotes by Alex Jinsung Choi, Chairman of the O-RAN ALLIANCE and Stefan Engel-Flechsig, O-RAN ALLIANCE’s COO
- Views on open RAN testing & integration and security by CSPs from Asia, Europe and Americas
- Industry panel discussions on regional development (deployments and trials), security, ecosystem maturity and energy efficiency by key CSPs and vendors from the O-RAN ecosystem
Follow our website for speaker lineup and further updates.
More than 60 O-RAN member companies plan to present demonstrations of their O-RAN based technology and solutions at MWC Barcelona or the O-RAN Virtual Exhibition and welcome visitors to join their booths. O-RAN ALLIANCE plans to issue a map of the demos at the exhibition. Follow us on the O-RAN ALLIANCE LinkedIn channel to learn more, closer to the event.
O-RAN Software Community 7th release “G” expanded to 13 project streams
In December 2022, following on the half year release cycle, the O-RAN Software Community (OSC) published its 7th open software release named "G". For the G release, the OSC expanded to 13 project streams, adding a new AI/ML Framework project.
With each release, OSC’s open software continues to greatly help companies to develop, test and integrate their commercial open and intelligent RAN solutions. Contributions to OSC’s open software come from a diverse community, delivering a broad scope of software according to latest O-RAN ALLIANCE specifications.
"I am so delighted to see the 7th release and the addition of the new AI/ML Framework project stream from our open source community," said Chih-Lin I, Chief Scientist from China Mobile and Co-chair of O-RAN Technical Steering Committee. "With O-RAN ALLIANCE moving into its 5th year, we look forward to evolving towards a new phase. I deeply believe that the power of open source is essential in pushing O-RAN's progress to new heights in the coming years."
“The growth of the O-RAN Software Community has been tremendous. With the O-RAN SC G release, this milestone will help further accelerate O-RAN globally and advance the deployment of flexible networks demanding carrier-grade cloud-native infrastructure as we move towards an intelligent systems world fueled by innovative edge applications,” said Gil Hellmann, vice president, Telecom Solutions Engineering, Wind River. “For the latest O-RAN SC G release, Wind River has continued to provide key contributions to the INF project by working with the community to enable more Open RAN related features in StarlingX and implementing a framework supporting the latest published O2 interface, which is pivotal to cloud infrastructure management and deployment operations. We look forward to continuing our close collaboration.”
New Open Testing and Integration Centres (OTIC) approved in Japan and North America
O-RAN ALLIANCE is pleased to announce Japan OTIC and North American OTIC in NYC Metro Area/East (COSMOS) joining the community of Open Testing and Integration Centres. With this addition there are now 9 approved OTICs across Europe, the Americas and Asia.
“Shared testing and integration are key to delivering commercial O-RAN solutions, so it is great to see more OTICs being approved in North America and around the world,” said Igal Elbaz, Network CTO of AT&T and Board member of O-RAN ALLIANCE. “OTICs are also part of O-RAN PlugFests and the O-RAN Certification and Badging program, promoting more confidence in O-RAN products, components, and solutions within the industry.”
"We are delighted with the start of Japan OTIC, pinned by the opening ceremony last month, and believe the neutral and open testing environment for vendors will help to advance O-RAN solutions," said Naoki Tani, EVP and CTO at NTT DOCOMO and Board member of O-RAN ALLIANCE. "NTT DOCOMO has deployed 5G networks nationwide with O-RAN compliant equipment and intends to further expand the O-RAN ecosystem as co-host of Japan OTIC together with YRP R&D Promotion Committee and Japanese operators.”
For more about O-RAN ALLIANCE testing and integration efforts and the OTICs, please visit our website.
About O-RAN ALLIANCE
The O-RAN ALLIANCE is a world-wide community of more than 300 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN specifications enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN based mobile networks at the same time improve the efficiency of RAN deployments as well as operations by mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.
For more information, please visit www.o-ran.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230118005984/en/
Contact information
O-RAN ALLIANCE PR Contact
Zbynek Dalecky
pr@o-ran.org
O-RAN ALLIANCE e.V.
Buschkauler Weg 27
53347 Alfter/Germany
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom